Osimertinib for maintenance treatment of EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy [ID6223]

  • In development
  • GID-TA11232
  • Expected publication date: 

Documents

Documents created during the development process.

Final draft guidance

Declaration of interests

Draft guidance

Committee meetings

  • Committee meeting

  • Committee meeting: 2

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6223

Notes

Topic selection